Erasca, Inc. disclosed it received a letter from Revolution Medicines accusing its cancer drug ERAS-0015 of patent infringement and trade secret theft. Following this announcement, Erasca's share price dropped nearly 48%, from $19.15 to $9.90. A law firm, Bragar Eagel & Squire, is investigating potential legal claims on behalf of Erasca shareholders regarding possible securities law violations. Investors who suffered losses are encouraged to contact the firm for more information and legal options.
nVent Electric plc announced a quarterly cash dividend of $0.21 per ordinary share, payable on August 7, 2026, to shareholders recorded by July 24, 2026. This dividend reflects nVent's ongoing commitment to returning value to shareholders. The compan...
OpenAI is consolidating its core AI products—ChatGPT, Codex, and its developer API—into a single product team to sharpen focus ahead of a potential IPO later this year. Greg Brockman, previously interim product lead, is now permanently in charge of p...
NextEra Energy and Dominion Energy are in talks to merge in a deal valued around $400 billion, creating one of the largest utility companies in the U.S. This merger aims to address the rapidly growing electricity demand driven by AI data centers, ind...
The Advent Convertible and Income Fund (AVK) maintains a buy rating due to its attractive 8.32% discount to net asset value (NAV) and a strong 10.9% dividend yield. The fund's strategy combines convertible securities, high-yield debt, and equities, f...
In 2026, the Teucrium Wheat Fund (WEAT) surged 24.29% driven by wheat-specific supply disruptions, outperforming the Invesco DB Agriculture Fund (DBA), which returned 10.7% by diversifying across multiple commodities. WEAT's gains reflect geopolitica...
